To achieve micro-elimination of HCV in high-risk groups, early detection of acute HCV is important in order to link individuals into care/treatment and harm-reduction programmes. Current guidelines suggest regular anti-HCV screening with additional HCV-RNA for high-risk individuals with unexplained elevated serum aminotransferases. HCV core antigen (HCV-cAg) offers an alternative to HCV-RNA testing to confirm HCV viraemia. We describe the use of HCV-cAg testing for early diagnosis of acute HCV in high-risk individuals attending for sexual health screening (SHS) at a large central London Sexual Health/HIV clinic.
Architect HCV-cAg testing (Abbott Diagnostics) was introduced in 5/2015 replacing anti-HCV to screen all high-risk patients attending for a SHS. High-risk HIV+ patients were offered 3-6 monthly screening in addition to routine 6-monthly HIV-monitoring blood tests (inclusive of liver function tests). All HCV-cAg positive samples were tested for HCV-RNA. We reviewed all acute HCV diagnoses screened with HCV-cAg from 5/2015–5/2018. Data were collected on patient demographics, HIV status, HCV reinfection, HCV genotype, anti-HCV and seroconversion, transmission risk factors and serum ALT.
76 acute HCV infections were diagnosed; all men, 98.7% MSM, 80% Caucasian, median age 44.5 years, majority (64/76, 84%) HIV co-infected. 9 (12%) were HCV re-infections; 8/9 HIV co-infected. 73/76 (96%) were diagnosed with a positive HCV-cAg test; 3/76 (4%) had negative HCV-cAg but were HCV RNA+ (all 3 had raised ALT >300 at diagnosis). Median ALT at HCV diagnosis was 138 IU/l (IQR 67-360). 11 (15%) had ALT <50 IU/l at time of first HCV-cAg+. All were HCV RNA+. Median time to peak ALT was 36 days (IQR 6.5-66.5) from first HCV-cAg+. 41/67 (61%) had anti-HCV testing at HCV diagnosis; 18 (44%) were anti-HCV+; 15/23 seroconverted a median 37 days (IQR 21-64) later. Table 1 summarises risk-factors and HCV characteristics. If acute HCV diagnosis was dependent on anti-HCV seroconversion and HCV-RNA testing with raised ALT, 34 (45%) patients may have been missed at the visit diagnosis was made.
Screening for acute HCV infection with HCV-cAg test provides an effective tool for early detection of HCV in high-risk populations. HCV-cAg tests are cheaper with a quicker turnaround time than HCV-RNA tests. The addition of ALT testing to a screening strategy based on HCV-cAg maybe a cost-effective method to reliably detect acute HCV cases.